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Abstract 
The amyloid precursor protein plus presenilin-1 (APP/PS1) mice are a frequently-used model for 
Alzheimer’s disease studies (AD). However, the data relevant to which proteins are involved in 
inflammatory mechanism are not sufficiently well-studied using the AD mouse model. Using 
behavioral studies, quantitative RT-PCR and Western-blot techniques, significant findings were 
determined by the expression of proteins involved in inflammation comparing APP/PS1 and Wild 
type mice. Increased GFAP expression could be associated with the elevation in number of reactive 
astrocytes. IL-3 is involved in inflammation and ABDF1 intervenes normally in the transport across 
cell membranes and both were found up-regulated in APP/PS1 mice compared to Wild type mice. 
Furthermore, CCR5 expression was decreased and both CCL3 and CCL4 chemokines were highly 
expressed indicating a possible gliosis and probably an increase in chemotaxis from lymphocytes and 
T cell generation. We also noted for the first time, a CCR8 increase expression with diminution of 
its CCL1 chemokine, both normally involved in protection from bacterial infection and 
demyelination. Control of inflammatory proteins will be the next step in understanding the 
progression of AD and also in determining the mechanisms that can develop in this disease. 
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Introduction 
Alzheimer’s disease (AD) is a common 
multifactorial neurodegenerative disorder that occurs 
mainly with aging. The neuropathological hallmarks 
of AD are amyloid plaques, intraneuronal tangles, 
and activation of glial cells [1-4]. Glial swelling and 
astrogliosis are a characteristic reaction of astrocytes 
to inflammation, oxidative stress and trauma, leading 
to the secretion of several potentially toxic products, 
including inflammatory agents [1] and oxidative 
stress mediators [5]. Data from our laboratory have 
shown the possible pathway to increase 
mitochondriogenesis and anti-inflammatory proteins 
to recover from amyloid beta (Aβ) action in primary 
culture neural cells [6]. Aβ deposition can result in 
brain damage but whether different chemokines in 
brain could participate in the Aβ-induced brain 
damage and neurodegeneration is unclear. Our study 
evaluates first, if changes in young and old-mice 
behavior occur. Second, whether changes in 
chemokine expressions, which act in inflammatory 
processes with chemotaxis and infiltration across 
blood- brain barrier (BBB), take place in transgenic 
APP/PS1 mice aged 7 months and 22-24 months, as 
we demonstrated previously in cells in primary 
culture [6-9]. Chemokine signaling has been 
implicated in the pathogenesis of diabetic neuropathy 
but the involvement of the chemokine CC motif 









(CCR8) expressions remain unknown in AD. Different 
authors, have demonstrated the involvement of 
chemokines in APP/PS1 mice. Zhu et al. [10] have 
showed an increase in CCL4 mRNA and protein 
expression in the brains of APP/PS1 mice vs. controls. 
This data is consistent with a potential inflammatory 
contribution to the neurodegenerative cascade in this 
model [10]. Also, high CCL4 expression has been 
found in multiple tissues affected by chronic 
inflammatory disease including AD [11]. In AD 
patients and in AD animal models, included 
APP/PS1, the chemokine CXCL10 is found in high 
concentrations, suggesting a pathogenic role for this 
chemokine and its receptor, CXCR3 [12]. Furthermore, 
plaque burden and Aβ levels were strongly reduced 
in CXCR3-deficient APP/PS1 mice and CXCR3 
antagonist increased microglia Aβ phagocytosis [12]. 
In other chemokines, such as CCL11 was increase 
observed in APP/PS1 double transgenic mice [10]. 
CCL11, which is predominantly expressed by the 
activated microglia, was observed in the cerebrospinal 
fluid of APP/PS1 double transgenic mice compared 
with wild-type (WT) mice. Also, the deletion of CCR3 
in APP/PS1 mice significantly reduced the 
phosphorylation of CDK5 [13]. The goal of this study 
was to examine, for the first time, the protein 
expression of CCL1 chemokine and its receptor CCR8, 
and also expression of the chemokines CCL3, CCL4, 
CCL5 and their receptor CCR5 in APP/PS1 mice, 
implicated in brain damage. Our findings may lead to 
more specific control of inflammatory changes that 
occur in AD brain.  
Material and Methods 
Animals 
APP/PS1 mice (B6C3-Tg) and wild type 
littermates were used. APP/PS1 mice express a 
chimeric mouse/human APP 695 cDNA containing 
the Swedish (KM670/671 NL) mutation co-integrated 
with the human presenilin 1 (PS1) gene harboring the 
DE9 mutation. Two groups were assayed, APP/PS1 
and Wild type mice and both of them were fed ad 
libitum on standard diet (Letica, Barcelona, Spain). 
Mice were kept on a 12-h light/12-h dark cycle with 
the room temperature maintained at 22ºC. All animal 
procedures were carried out in accordance with the 
European legislation on the use and care of laboratory 
animals (CEE 86/609). Experimental research on mice 
was performed with the approval of the ethics 
committee on animal research of the University of 
Valencia (Spain). 
Behavior studies 
APP/PS1 and Wild type mice (N=25, 6 months) 
were used to examine motor function and memory 
and learning functions using active avoidance and 
object recognition tests and motor coordination 
(rotarod test). The tests were performed at different 
ages (at 7, 21 and 24 months). 
Active avoidance 
The active avoidance task is designed to test the 
ability of the mice to avoid an aversive event by first 
learning to perform a specific behavior in response to 
a stimulus cue. The test was performed in one single 
day and consisted of 50 trials per animal, as 
previously described [14]. 
Object recognition test 
This test exploits the tendency of mice to 
preferentially explore novel elements of their 
environment or the same element located in different 
position. Thus, when a mouse is presented with both a 
novel and recently presented familiar object, it will 
spend significantly more time exploring the novel 
object (object recognition memory). When a mouse is 
presented with two identical known objects but one of 
them is located in a different position it will spend 
significantly more time exploring the object in the 
new location (object location memory test). The 
familiar objects were presented in a previous training 
session 1 h before the test. The percentage of time 
exploring the non-familiar object in the training 
session over total exploration time (exploration time 
of the familiar plus the non-familiar objects) was 
represented. The object recognition or location index 
was calculated as follows: time of exploration of novel 
object (or the same object in a new location-time of 
exploration of familiar object + time of exploration of 
novel object) [15].  
Balance beam test 
This task is used to assess sensorimotor function 
and balance in rodents.  
In this test, the ability of mice to pass through a 
narrow beam to reach a dark box is evaluated. To 
force mice to pass through the beam, a white light 
illuminates the beginning of the beam. The wooden 
beam (1 x 100 cm) was elevated to a height of 1 m 
above the floor. The time required to cross to the 
escape box at the other end of beam and the number 
of forelimb and hind-limb paw slips were recorded. A 
paw slip was defined as any paw coming off the top of 
the beam or any limb use on the side of the beam. The 
day of the test, four trials were performed before 
recording the results. The goal was to familiarize the 
mice to the beam and to train them to the presence of 
the dark box at the end of the beam. The narrow beam 
and the dark box were cleaned after each trial with 
ethanol. The latency between trials. 





Grip strength  
Grip strength is measured non-invasively by 
taking advantage of the mouse’s instinctive tendency 
to grab as they are gently pulled backward. This 
method can be used to test for limb grip using a 
horizontal bar with small diameter 0.1 cm which is 
attached to a force transducer. The advantages are 
that the grip strength is reproducible and can be 
measured repeatedly in rodents to detect progressive 
motor deficits, value of therapy and genetic 
modifications [16]. Mean latency to fall was 
determined with a maximum cut-off at 60 s. 
Biochemical studies 
APP/PS1 and Wild type mice (N=10, 6 months) 
were used. All the biochemical studies were done in 7 
month-old mice. 
Real-time polymerase chain reaction analyses 
Cortical brain samples were collected from each 
mouse into an RNAlater solution (Ambion, Austin, 
TX, USA), an RNA stabilization reagent, following the 
manufacturer's instructions. Total RNA was extracted 
with Tripure isolation reagent (Roche Molecular 
Biochemical, Basel, Switzerland) and concentration 
and integrity were assessed in RNA 6000 Nano 
Labchips using Agilent 2100 Bio-analyzer (Agilent 
Technologies, Foster City, CA, USA). Ready-to-use 
primers and probes from the assay-on-demand 
service of Applied Biosystems were used for the 
quantification of selected target gene: CCL1 
(Mm99999220_Mh), CCL3 (Mm00441259_g1), CCL4 
(Mm00443111_m1), CCL5 (Mm01302428_m1), CCR5 
(Mm01963251_s1), CCR8 (Mm99999115_s1), ABCF1 
(Mm01275245_m1), IL-3 (Mm00439631_m1), and 
endogenous reference gene β-actin (Mm00607939_s1). 
RNA samples were reverse-transcribed using random 
hexamers and MultiScribe reverse transcriptase 
(Applied Biosystems). After complementary DNA 
synthesis, real-time polymerase chain reaction 
(RT-PCR) was carried out using the ABI Prism 
7900HT Sequence Detection System (Applied 
Biosystems). Samples were run in triplicate, and 
expression changes were generated by calculating 
2-ΔΔCt. 
Western-blot analysis 
Protein extracts from cortex brain were mixed 
with equal volumes of SDS buffer (0.125 M Tris-HCl, 
pH 6.8, 2% SDS, 0.5% (v/v) 2-mercaptoethanol, 1% 
bromophenol blue and 19% glycerol) and then boiled 
for 5 min. Protein concentration was determined 
using a modified Lowry method [17]. Proteins were 
separated by SDS-PAGE gels and transferred to 
nitrocellulose membranes using standard techniques. 
Membranes were blocked with 5% dried milk in TBS 
containing 0.05% Tween-20 and then incubated with 
the corresponding antibodies following 
manufacturer's recommendations. The blots were 
washed three times with a washing buffer 
(phosphate-buffered saline, 0.2% Tween 20) for 15 
min each and then incubated for 1 h with a secondary 
horseradish peroxidase-linked anti-rabbit or 
anti-mouse IgG antibody (Cell Signaling 
Technologies, Barcelona, Spain). As above, the blots 
were washed three times and developed using the 
enhanced chemiluminescence (ECL) procedure as 
specified by the manufacturer (Pharmacia 
biotechnology, San Francisco, CA, USA). 
Auto-radiographic signals were assessed using a 
Bio-Rad scanning densitometer. Antibodies: 
Monoclonal anti-glial fibrillary acidic protein (GFAP) 
and anti-microtubule associated protein 2 (MAP-2) 
from Santa Cruz Biotechnology. Monoclonal 
anti-CCR5 antibody and anti-CCR8 antibody from 
Abcam Biotechnology. All other reagents are 
analytical or culture grade purity. 
Data analysis and statistics 
All values are expressed as means ± SD. The 
differences between transgenic (APP/PS1) and Wild 
type (WT) mice were determined with unpaired 
Student’s t-test. All statistical analyses were 
performed using the Graph-Pad Prism software 
(GraphPad Software Inc., San Diego, CA, USA). 
Statistical significance was accepted at p values < 0.05. 
Results 
General motor, muscular impairment and 
coordination  
The ability of mice to pass through a narrow 
beam showed the difference of activity between 
APP/PS1 and Wild type mice using the behavior 
activity of the beam-walking test. Behaviorally, 
APP/PS1 mice at 7 and 22-24 months did not display 
general motor and muscular impairment as 
demonstrated by unaffected exploratory cage activity, 
grip strength and toe hold ability to cross a beam in 
the beam-walking test (Figure 1 A-C).  
By contrast, a significant number of foot faults in 
the beam-walking test was observed in APP/PS1 mice 
22-24 months compared to Wild type mice (p<0.001) 
(Figure 1D).  
Recall spatial information and memory test. 
The ability of mice to acquire and recall spatial 
information was assessed by active avoidance task 
and by object recognition test. In the memory test, 
APP/PS1 mice displayed memory impairment on 
both object recognition (p<0.001) and object location 





memory (p<0.05) compared to Wild type mice 
(Figures 2 A-B). Memory changes were not detected in 
7 month mice. 
Expression of GFAP and MAP-2 on the 
APP/PS1 mice. 
Alterations in motor, memory and object 
recognition may be related to brain inflammation, 
demyelination and cell infiltration in APP/PS1 mice. 
APP/PS1 mice show increase in Aβ generation and 
accumulation and activation of astrocytes and 
microglia is critical in this process. For this reason, we 
determined by Western-blot both GFAP and MAP-2 
expression. GFAP is an astrocyte protein marker and 
MAP-2 a marker of microtubule assembly in neurons. 
Our results showed that expression of GFAP was 
higher in APP/PS1 cortex at 7 months compared with 
Wild type mice (Figure 3A), which could indicate an 
increase in the number of astrocytes in APP/PS1 
compared to Wild type mice. Conversely, we noted a 
decrease in MAP-2 expression on APP/PS1 compared 
with Wild type mice (Figure 3B).  
Expression of CCL1 chemokine and its CCR8 
receptor in brain cortex.  
In the present study, we determined mRNA 
expression of CCL1 chemokine by real-time RT-PCR 
from APP/PS1 and Wild type cortex in mice. Also we 
assessed CCR8 protein expression by RT-PCR and 
Western-blot techniques in all mice. CCL1 expression 
was higher in Wild type compared with APP/PS1 
mice (Figure 4A) and CCR8 showed higher expression 
in APP/PS1 compared to Wild type mice (Figure 4B 
and 4C), demonstrating different expression values 
between CCR8 and its chemokine in cortex of 
APP/PS1 and Wild type mice. This expression was 
inversely correlated with the expression of CCL1 in 
APP/PS1 mice.  
 
 
Figure 1. Behavior assays. A: Exploration of two identical object (sec in 5 minutes), with no significantly differences between wild type (WT) and transgenic (TG) mice. B: Grip 
strength (time in 60 seconds). C: Time to cross the beam (sec). D: number of foot faults, ***p<0.01 vs. wild type mice. 
 
Figure 2. Object location memory and object recognition memory. A: object recognition memory (discrimination index), ***p<0.01 vs. wild type mice. B: object location 
memory (discrimination index), *p<0.05 vs. WT mice. 






Figure 3. Protein expression of A: GFAP and B: MAP-2 in cortex of APP/PS1 and WT mice. A representative immunoblot is shown in the panel. Data are mean ± SD of four 
independent experiments. *p<0.05 vs. WT. 
 
Figure 4. mRNA expression of A: CCL1 and B: CCR8 in cortex of APP/PS1 and WT mice. C: Protein expression of CCR8 by Western-blot. A representative immunoblot is 
shown in the panel. Data are mean ± SD of four independent experiments. *p<0.05 vs. WT. 
 
Expression of CCL3, CCL4, CCL5 chemokines 
and the CCR5 receptor.  
Here we detected a higher CCL3 and CCL4 
expression without a different expression in CCL5 
chemokine in APP/PS1 to Wild type mice (Figure 5A, 
5B, 5C). We therefore performed real-time RT-PCR 
and Western-blot methods expression of CCR5 in 
mouse brain cortex. CCR5 expression decreased in 
transgenic compared to Wild type mice (Figure 5D 
and 5E).  
IL-3 mRNA expression in APP/PS1 transgenic 
compared to Wild type mice. 
IL-3 regulates the proliferation, survival and 
differentiation of hematopoietic cells and has been 
detected in the CNS, but its physiological role in 
neural cells is poorly understood in AD. IL-3 prevents 
neuronal death induced by Aβ and has been detected 
in higher expression in AD, demonstrating that IL-3 
could play a neuroprotective role in AD. We showed 
here an increase in IL-3 expression in APP/PS1 
compared to Wild type mice (Figure 6A).  
ABCF1 mRNA expression in APP/PS1 
compared to Wild type mice. 
ABCF1 gene expression was determined. The 
ATP binding cassette (ABC) super-family of proteins 
are present in brain and harness the energy from the 
hydrolysis of ATP in order to transport substrates 
across cellular membranes and power cellular 
machinery. ABCF1 can import and export molecules 
across the cell and was initially identified as a protein 
that was up-regulated in synoviocytes. Also ABCF1 is 
important in translation initiation. Here, we found 
that its expression is higher in APP/PS1 compared 
with Wild type mice, and increase 3 times respect to 
Wild type mice (Figure 6B).  






This study indicates that changes in chemokines 
and chemokine receptors are important in the 
involvement of inflammation in AD and one of the 
possible causes for the development of this disorder. 
This finding suggests BBB damage and chemotaxis 
occur with inflammatory consequences in the brain. 
In addition, the molecules movement across cell 
membranes could be possibly higher in transgenic 
mice compared to Wild type mice which suggests that 
compensation of energy loss occurred in transgenic 
mice compared with Wild type mice as evidenced by 
the results obtained with the changes in ABCF1 
protein. Demyelination occurs due to an increase in 
CCR8, as different authors have suggested, and as we 
have confirmed here (Figure 7).  
 
 
Figure 5. mRNA expression of A: CCL3, B: CCL4 and C: CCL5 and D: CCR5 by Western-blot in cortex of APP/PS1 and WT mice. A representative immunoblot is shown in 
the panel. Data are mean ± SD of four independent experiments. *p<0.05 vs. WT. 
 
Figure 6. mRNA expression of A: IL-3 and B: ABCF1 in cortex of APP/PS1 and WT mice. Data are mean ± SD of four independent experiments. *p<0.05 vs. WT. 
 
Figure 7. Inflammatory protein changes in APP/PS1 mice. The schema shows the up-regulation or down-regulation of different proteins. Pro-inflammatory mediators, such as 
CCL3 and CCL4, are increased. By contrast, CCR5 is down-regulated. The protein ABCF1 (a member of the superfamily of ATP-binding cassette (ABC) transporters) is 
increased. IL-3 (involved in the immune system) is highly expressed. Also CCR8 is increased (important for the migration of various cell types into the inflammatory sites). 





Our previous results demonstrated that Aβ 
peptide causes oxidative stress in neurons [8] and in 
astrocytes in primary culture [9]. Others have 
demonstrated that secretion of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) by 
inflammatory cells is a major mechanism for attacking 
opsonized targets while activated glial cells can 
produce large amounts of ROS/RNS by various 
mechanisms [10]. The APP/PS1 mice is well known 
model of AD and the behavior deficits are not 
detected until an elderly age in mice. Our present 
results indicate that the alterations in the cortex of 7 
month APP/PS1 mice take place before deficits in 
behavior appear. In the present study we show that 
transgenic mice (APP/PS1) (22-24-months) display 
severe motor incoordination and amnesic impairment 
on both object recognition memory and object location 
memory. On the contrary, behavior experiments with 
7 month mice did not show changes between 
transgenic and Wild type mice in this study. The 
present study aimed to evaluate also whether a 
deregulation of the expression of certain chemokines 
involved in demyelination, phagocytosis and 
chemotaxis, occurs in the APP/PS1 mice. The 
measurements were made in the cortex of 7 month 
APP-PS1 mice because this is the second brain region 
most affected when memory is damaged. Our data 
shows a decrease in CCL1 expression and an 
increased expression of its receptor CCR8 and also an 
upregulation of CCL3 and CCL4 chemokine 
expressions with a reduced expression of their 
receptor CCR5 in APP/PS1 mice compared to Wild 
type mice. CCR8 encodes a member of the beta 
chemokine receptor family and its ligand is CCL1 [18]. 
Here, we detected for the first time, changes in 
expression of CCR8 and its chemokine, CCL1 in 
APP/PS1. CCR8 expression was increased in 
transgenic mice, indicating a rise in receptor 
expression to supply downregulation of its 
chemokine CCL1. CCL1 attracts immune cells by 
interacting with the cell surface chemokine receptor 
CCR8 [19] and contributed to the development of 
neuropathic pain [20]. CCR8 expression is controlled 
by skin-specific factors derived from epidermal 
keratinocytes and not by resident dendritic cells. It is 
also expressed in neurons, microglia and astrocytes 
[21] and has been reported to accumulate microglial 
cells in the CNS of APP/PS1 [21]. This is related to the 
action of promoting chemotaxis of mononuclear cells 
and phagocytosis [22]. Trebst et al., suggested that 
CCR8 is not expressed in Alzheimer's type 
macrophages surrounding senile plaques [23]. Trebst 
et al. data include tissue from AD humans, whereas 
our results were done in 7 month APP/PS1 mice 
(corresponding to nearly 30 years old in human). At 
this age in humans, Aβ1-42 plaques are detected and 
probably eliminated. On the other hand, there is no 
elimination of those plaques in elderly AD patients. 
Perhaps expression of CCR8 disappears when AD has 
developed. The combination of 1α,25-dihydroxy-
vitamin D3 and prostaglandin E2 (PGE2) results in a 
high CCR8 expression, demonstrating the importance 
of tissue environments in maintaining cellular 
immune surveillance networks within distinct healthy 
tissues [24]. This receptor is expressed on primary 
cultured microglia and astrocytes and CCL1 mRNA is 
more robustly expressed in neurons than in glia [21]. 
This data indicates that CCL1 works as a mediator 
between neuron and microglia in the CNS. Thus, a 
decrease in CCL1 expression, such as we observed, 
could indicate a reduction in communication between 
neurons and glia and also a decrease in neuron 
density in APP/PS1 mice as we show by a reduction 
of MAP-2 expression.  
Inflammation occurs in Alzheimer disease with a 
production of cytokines and chemokines inducing 
progression of the inflammatory cascade [25, 26]. 
Lipopolysaccharide stimulation of primary microglial 
cultures is reported to diminish the levels of CCL1 in a 
diabetic neuropathy mouse model [27]. Our results 
support the hypothesis that CCL1 has an important 
role as a mediator in neuro-immune interactions and 
that CCL1/CCR8 cross-talk contributes to the 
development of inflammation in AD. Another key 
function of CCL1 is the role in microglial phagocytosis 
eliminating neurotoxic molecules, cellular debris or 
microbes [23]. A decrease in CCL1 expression could 
explain the decline in elimination of Aβ by 
phagocytosis detected in AD [28]. In Taiep rats, an 
upregulation in CCR8 mRNA and protein were 
detected at 1 month old, explaining the accumulation 
of microglial cells in the CNS due to the action of 
promoting chemotaxis and phagocytosis [29].  
The volume of the human brain has important 
variation especially in relation to age. Interleukin-3 
(IL-3) is reported to be strongly associated with brain 
volume changes [30]. Moreover, IL-3 receptor alpha is 
expressed in neural progenitors and neurons, and 
promotes proliferation and survival of neural 
progenitors with novel roles of IL-3 in regulating 
brain development [30]. Here we show that IL-3 is 
highly expressed in APP/PS1 mice indicating possible 
changes in brain volume and confirming previous 
findings [30]. Furthermore, correlation between IL-3 
and CCR8 has been detected in transcriptional 
analysis of multiple sclerosis brain lesions 
demonstrating a complex pattern of cytokine 
expression in this disease [31]. Also, overexpression of 
CCR5 and IL-3 has been detected in severe 
tuberculosis [32].  





CCR5 is expressed in neurons associated with 
memory and in monocytes, macrophages, astrocytes, 
and microglia as well as in epithelium, endothelium, 
vascular smooth muscle, and fibroblasts [33]. The 
pro-inflammatory cytokines CCL3, CCL4 and CCL5 
are its ligands, involved in the effector responses [34]. 
Here we detected a downregulation of CCR5 in 
APP/PS1 mice with upregulation of CCL3 and CCL4 
chemokines and without changes in CCL5 expression. 
The role of CCR5 has been mainly studied in the 
context of HIV (human immunodeficiency virus) 
infection [35]. In 1996, different laboratory groups 
indicated that CCR5 is a major co-receptor for the 
entry of HIV into target cells [36-38]. But the receptor 
is also expressed in the CNS [39-41] and in addition, to 
the modulation of immune response. CCR5 can 
influence neuronal survival and has been suggested to 
be involved in neuroprotective mechanisms [42]. It is 
important to note that the cell death in the brains of 
CCR5-/- mice are significantly higher than in the 
brains of CCR5+/+ mice [43] and also an increase of 
reactive astrocytes exist in these mice, suggesting that 
absence of CCR5 leads to the activation of astrocytes. 
Furthermore, CCR5 is implicated in neuronal growth 
and differentiation during development and is related 
to striatal dopamine release [44]. Deletion of CCR5 
could be implicated in a deficient development and 
maturation of dopaminergic neurons and prevents 
macrophage infiltration and demyelination [45, 46]. 
Moreover, Hwang and collaborators have indicated 
an increase in Aβ deposits and impaired memory 
when CCR5 declines and supports cell death that 
occurs in AD patients [47]. In the brain of CCR5 
knockout mice, LPS injection significantly increases 
astrogliosis, β-secretase expression and Aβ deposition 
compared with CCR5 Wild type mice. Furthermore, 
deficiency of CCR5 results in activation of astrocytes 
and Aβ deposits [47]. 
We here detected an increase in chemokines 
CCL3 and CCL4 expression in cortex of 7-month-old 
APP/PS1 mice. There could be two possibilities for 
this finding. First, by the increment of the chemokines 
CCL3 and CCL4 that have as consequence the 
decrement in CCR5 expression, or contrarily, by 
decrease in CCR5 expression that produces an 
increase in CCL3 and CCL4 chemokine expressions. 
According to our data we cannot deduce what is the 
sequence of events that would lead to that process in 
APP/PS1 mice. Studies by Man and collaborators [48] 
show that AD patients had a higher CCL3 level 
compared to healthy controls in peripheral T 
lymphocytes. A study in 2017, demonstrated that an 
increase in CCL3 expression produced accumulation 
of glial cells, monocytes and lymphocytes in a 
hypoxia mouse model and probably contributes to the 
pathogenesis of AD [49]. Furthermore, CCL3 is 
upregulated in the CNS during Alzheimer’s disease 
[50, 51] and is located in microglia, astrocytes and 
perivascular macrophages [52, 53]. CCL3 is a member 
of β-chemokine subfamily and is involved in the 
recruitment and activation of polymorph-nuclear 
leukocytes. Accumulated T cells lead to the increased 
levels of pro-inflammatory cytokines and cause 
chronic inflammation, which enhance neurotoxicity 
and impair microglial function [54]. Cell infiltration in 
the brain might also contribute to the cognitive 
impairment of tau pathology. Other authors found 
that hippocampal T cells might modulate microglial 
and/or astrocytic activation status and lead to 
detrimental impact on synaptic plasticity [55]. 
Furthermore, CCL3 is constitutively expressed by the 
nigral dopaminergic neurons and modulates 
neurotransmission by liberating transmitters across 
ion-channel gating and also long-term potentiation 
[56]. Others have indicated that active transport of 
CCL3 across the BBB in vitro at the luminal side 
occurs independently of the chemokine receptors 
CCR1 and CCR5. Moreover, leukocyte transporter 
was decreased in inflammatory conditions [57], 
suggesting additional pathways to increase immune 
cell transport across BBB. One of those pathways, we 
hypothesize could be ABCE1. CCL4 mRNA and 
protein are upregulated in APP/PS1 mice compared 
with Wild type and correlates with Aβ increased 
levels [13]. These authors also demonstrated a 
relationship among astrocytes, Aβ and CCL4 location 
in the brain of APP/PS1 transgenic mice. Astrocytes 
are the source of Aβ1-42 because they produce an 
overexpression of β-secretase (BACE1), an enzyme 
that cleaves amyloid precursor protein (APP) to 
produce Aβ [58] which accelerates Aβ1-42 deposition 
and can possibly result in impaired memory function 
[59]. These results correlate well with the data 
published by Zhu and collaborators where a clean-up 
of amyloid toxicity occurs inside the brain of 
APP/PS1 mice [13]. Furthermore the production of 
CCL4 is controlled by peripheral blood mononuclear 
cells in AD patients [60]. Song and collaborators 
demonstrate an increase in deposition and soluble 
Aβ1-42 in the brain of TL4RM (Toll-like receptor 4 
mutation), which was associated with decreased 
expression levels of CCL4 and CCL3. This action 
increases cognitive functions in the hippocampus of 
these mice. Consequently, microglia is activated via 
TLR4 signaling to reduce Aβ deposits and preserve 
cognitive functions from Aβ-mediated neurotoxicity 
[61]. 
Our results also demonstrated a higher mRNA 
expression of ABCF1 in APP/PS1 compared to Wild 
type mice. ABCF1 is a member of the super-family 





ABC that can be divided in three categories, 
importers, exporters and DNA repair and translation 
[62]. ABCF1 lack trans-membrane domain so it falls 
into the third category [63]. Its function could be 
interacting in the initiation of translation through an 
interaction with eukaryotic translation initiation 
factor 2. Abcf1-/- mice are embryonic lethal and 
Abcf1+/- mice are fertile and develop normally in 
adults. This protein was highly correlated with active 
proliferation and differentiation of cell types [64]. 
Furthermore, it is expressed in many tissues, 
including brain, where it is particularly expressed in 
pyramidal cells, cerebellar Purkinje cells and in 
hippocampus. On the contrary, it is lower expressed 
in the pyramidal tracts and the thalamus [64]. 
Recently investigators have reported that ABCF1 is a 
critical mediator of N6-methyladenosine (m6A) 
translation promoter under both stress and 
physiological conditions [65], supporting the role of 
ABCF1 in illnesses such as AD.  
Conclusions 
Our results show that changes in chemokines 
and chemokine receptors expression could explain the 
induction of chronic inflammation and events such as 
demyelination, phagocytosis and chemotaxis which 
are likely involved in AD. Pro-inflammatory 
mediators, such as CCL3 and CCL4, are increased and 
by contrast, CCR5 is down-regulated indicating 
probably an increase in astrogliosis and number of 
astrocytes. In addition, we detected an increased 
expression by induction of IL-3 protein. The ABCF1 
increase detected here reinforces the idea of further 
investigation concerning the import and/or export of 
molecules between brain cells that may be affected in 
AD. Since chemokines can cross BBB in this mouse 
model of AD, disturbed normal physiology is 
expected. Chemotaxis with a possible accumulation of 
microglia and demyelination could be produced by 
CCR8 (Figure 7). These findings suggest that no 
appropriate crosstalk seems to occur between brain 
cells. 
Proper control of inflammatory chemokines, 
chemokine receptors and proteins helping molecules 
that cross cell membranes could be a potential next 
step in Alzheimer’s disease treatment. 
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